Pub. Date : 2017 Feb
PMID : 27718639
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Perspective: 4beta-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. | cholest-5-ene-3,4-diol | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 2 | Plasma 4beta-hydroxycholesterol (4beta-HC) is considered as an emerging endogenous biomarker for cytochrome P450 3A (CYP3A), one of the major drug metabolizing enzymes. | cholest-5-ene-3,4-diol | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 3 | Plasma 4beta-hydroxycholesterol (4beta-HC) is considered as an emerging endogenous biomarker for cytochrome P450 3A (CYP3A), one of the major drug metabolizing enzymes. | cholest-5-ene-3,4-diol | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 4 | Plasma 4beta-hydroxycholesterol (4beta-HC) is considered as an emerging endogenous biomarker for cytochrome P450 3A (CYP3A), one of the major drug metabolizing enzymes. | cholest-5-ene-3,4-diol | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 5 | Plasma 4beta-hydroxycholesterol (4beta-HC) is considered as an emerging endogenous biomarker for cytochrome P450 3A (CYP3A), one of the major drug metabolizing enzymes. | cholest-5-ene-3,4-diol | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 6 | Herein, we review the biology of 4beta-HC, its response to treatment with CYP3A inducers, inhibitors and mixed inducer/inhibitors in healthy volunteers and patients, the association of 4beta-HC with other probes of CYP3A activity (e.g. midazolam, urinary cortisol ratios), and present predictive pharmacokinetic models. | cholest-5-ene-3,4-diol | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |